What it is
Regulatory status: prescription medication (peptide hormone / recombinant biologic). Not a dietary supplement
At a glance
What it is, why people use it, the evidence, and what to know before trying it.
Why people use it
- **Linear growth in GH-deficient children** (approved).
- **Linear growth in selected non-GHD pediatric short-stature syndromes** (approved, brand-specific).
- **Body-composition repair in adults with documented GHD** (approved replacement).
- **Lean mass, weight, and endurance in HIV-associated wasting** (approved; Serostim).
- **Nutrient absorption support in adult short-bowel syndrome** (approved; Zorbtive).
- **Lean-mass gain and fat-mass loss in healthy adults** (off-label / illegal-distribution claim).
- **Rise in circulating IGF-1** (pharmacodynamic surrogate, often sold as if it were a benefit).
- **Athletic performance** — strength, aerobic capacity, sprint / anaerobic capacity (doping claim; WADA-prohibited).
- **Anti-aging / restored youth** — skin, vitality, bone, lifespan (off-label claim; not approved; US distribution for this use is illegal).
- **Improved insulin sensitivity or metabolic health** (sometimes claimed; physiology predicts the opposite).
Evidence at a glance
Somatropin is a **real hormone replacement and a real disease drug**. In children with approved growth indications it increases height velocity. In adults with **documented GHD** it modestly raises lean mass (~1.4–2.7 kg in meta-analyses; more in the small 1989 trial), lowers fat (~2.6–3.1 kg), and can improve some lipids, at the cost of edema, joint symptoms, and worse insulin sensitivity. In HIV wasting, high-dose short-course GH raised lean mass ~3 kg and treadmill work. Those are labeled uses. It is **not** an approved, evidence-based, or (in the US) lawful anti-aging or body-composition drug for healthy adults. The composition change in eugonadal adults is about **2 kg lean / 2 kg fat**, much of the lean is water, weight does not fall, strength and VO₂max do not improve, IGF-1 rises (a surrogate), and edema / arthralgia / carpal tunnel / glucose worsening are common. One 8-week trial found a small, reversible sprint-capacity bump. No trial has shown longer life or delayed age-related disease. Cancer data in childhood-treated isolated GHD are mostly reassuring into the mid-20s and **uninformative** for years of pharmacologic use in midlife.